Q1 2017 Results - With a particularly strong start to 2017, Unilabs delivers the 11th consecutive quarter of organic EBITDA growth
European medical diagnostics leader Unilabs reports a strong start into to 2017, delivering the 11th consecutive quarter of EBITDA growth. Commenting on the results, Jos Lamers, Chief Executive Officer stated, “What makes this quarter particularly noteworthy is that we have generated strong growth across both our Lab and Imaging segments as well as our various regions. This is also our 11th consecutive quarter delivering a sustainable organic EBITDA growth.” 
Unilabs subholding announces pricing of its senior notes offering
Unilabs SubHolding AB (publ) (the “Issuer”) today announced that it has priced its offering of €250,000,000 aggregate principal amount of 5.75% senior notes due 2025 (the “Notes”). The offering is expected to close on May 5, 2017.

Our Partnerships, Expertise & Network

We are a partner of choice and leading provider of outsourced diagnostic services with more than 200 diagnostic contracts across Europe.
Our services include: laboratory medicine, medical imaging, histopathology, reproductive medicine, and drug development services.
With operations in 12 countries, we are positioned as a regional leader with one of the broadest geographic coverage in Europe.